SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Kumar Nathan who wrote (257)2/1/1997 6:49:00 PM
From: scaram(o)uche   of 6136
 
(1) Welcome is part of Glaxo, and Glaxo's PI partner is Vertex.
(2) The Roche PI (saquinavir) is reknowned for poor bioavailability.
(3) Roche has more experience with "two PI" clinical trials than any other player, including Viracept plus saquinavir.
(4) Recent studies indicate that "two PI" therapies are very effective, and there is reason to believe that nucleosides may not be required for optimal results.

Your concern is wise, and several of the earlier posts in this thread address the issue. It will definitely be interesting to see what happens in Europe, and I propose that this partnership portends trouble for Glaxo/Welcome. We'll see. :-)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News